加味逍遥散治疗脑卒中后抑郁临床研究  

Clinical Study on Modified Xiaoyao Powder for Post-Stroke Depression

作　　者：龚全友 侯芳丽 刘华 秦朝霞 GONG Quanyou;HOU Fangli;LIU Hua;QIN Zhaoxia

机构地区：[1]河南省驻马店市中心医院,河南驻马店463000

出　　处：《新中医》2020年第24期38-40,共3页New Chinese Medicine

摘　　要：目的:观察加味逍遥散联合西医常规治疗脑卒中后抑郁的临床疗效。方法:将脑卒中后抑郁患者100例随机分为2组,观察组与对照组各50例。对照组在常规治疗的基础上加用盐酸氟西汀胶囊治疗,观察组在对照组的基础上加用加味逍遥散治疗。疗程均为2个月,观察比较2组治疗前后汉密顿抑郁量表(HAMD)评分变化,同时评估2组临床疗效。结果:总有效率观察组为92.0%,对照组为72.0%,2组比较,差异有统计学意义(P<0.05)。治疗后,2组患者HAMD评分均较治疗前明显下降(P<0.05);且观察组HAMD评分明显低于对照组(P<0.05)。结论:加味逍遥散治疗脑卒中后抑郁疗效肯定,能显著改善患者抑郁状态。Objective: To observe the clinical effect of modified Xiaoyao powder combined with western medicine for post-stroke depression. Methods:A total of 100 cases of patients with post-stroke depression were randomly divided into the control group and the observation group,50 cases in each group. Based on routine treatment,the control group was additionally treated with fluoxetine hydrochloride capsules,and the observation group was additionally treated with modified Xiaoyao powder based on the treatment of the control group. Both groups were treated for two months. Before and after treatment, the changes in scores of Hamilton Depression Scale(HAMD) in the two groups were observed and compared,and the clinical effect in the two groups was evaluated. Results:The total effective rate was 92.0% in the observation group and 72.0% in the control group, the difference being significant(P<0.05). After treatment, the HAMD scores in the two groups were significantly decreased when compared with those before treatment(P<0.05);the HAMD score in the observation group was significantly lower than that in the control group(P<0.05). Conclusion:Modified Xiaoyao powder for post-stroke depression has definite curative effect and can effectively improve depression of patients.

关 键 词：脑卒中后抑郁 盐酸氟西汀胶囊 加味逍遥散 汉密顿抑郁量表 

分 类 号：R749.4[医药卫生—神经病学与精神病学] R743.3[医药卫生—临床医学]